ZORYVE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZORYVE (ZORYVE).
ZORYVE (roflumilast) is a selective phosphodiesterase-4 (PDE4) inhibitor. It inhibits the degradation of cyclic AMP (cAMP), leading to increased intracellular cAMP levels, which reduces the release of pro-inflammatory cytokines and mediators from various immune cells (e.g., neutrophils, eosinophils, macrophages).
| Metabolism | Primarily metabolized by CYP3A4 and CYP1A2 to its active N-oxide metabolite (roflumilast N-oxide). |
| Excretion | Fecal (approximately 90% of absorbed dose as unchanged drug and metabolites), renal (approximately 10% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 28 hours; steady-state achieved within 2 weeks with once-daily dosing. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.7 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Approximately 5% systemic absorption; oral: not applicable (not available orally). |
| Onset of Action | Topical: Reduction in plaque elevation, erythema, and scaling observed within 2 weeks of twice-daily application. |
| Duration of Action | Sustained effect with once-daily dosing; clinical improvement maintained for up to 8 weeks of continuous use. |
| Molecular Weight | 340.42 |
Topical: Apply once daily to affected areas. For plaque psoriasis, use 0.3% cream; for seborrheic dermatitis, use 0.3% foam.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required based on GFR. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. For Child-Pugh C, use with caution; no specific dose recommendation. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established. |
| Geriatric use | No specific dose adjustment; elderly may have increased skin fragility, monitor for adverse effects. |
| 1st trimester | Insufficient human data; animal studies show no evidence of harm. Use only if potential benefit justifies potential risk. |
| 2nd trimester | Insufficient human data; recommend avoiding unless clearly needed. |
| 3rd trimester | Insufficient human data; may interfere with labor and delivery due to anti-inflammatory effects. |
Clinical note
Comprehensive clinical and safety monograph for ZORYVE (ZORYVE).
| Placental transfer | No direct human data; molecular weight (<500 Da) suggests possible placental transfer. Animal studies show limited transfer. |
| Breastfeeding | No human data on excretion in breast milk. Based on molecular weight and low oral bioavailability, systemic exposure to infant is likely low. However, due to lack of data, caution is advised. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to active ingredient or any excipients
| Precautions | Not for ophthalmic, oral, or intravaginal use, Patients with moderate-to-severe liver impairment: not recommended, May cause hypersensitivity reactions, including contact dermatitis, Use in pregnant women: limited data; consider risk vs benefit |
| Food/Dietary | No clinically significant food interactions. Grapefruit may increase roflumilast exposure via CYP3A4 inhibition; avoid concurrent intake. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, oral administration of roflumilast during organogenesis produced fetal developmental toxicity (including increased post-implantation loss, reduced fetal body weight, and delayed ossification) at exposures approximately 100 times the maximum recommended human dose (MRHD). However, with topical application, systemic exposure is minimal (<5% bioavailability), resulting in negligible fetal exposure. Therefore, based on topical route, risk is expected to be low. First trimester: insufficient data; second and third trimesters: same as first, but theoretical risk remains low due to minimal systemic absorption. |
| Fetal Monitoring | No specific monitoring required beyond routine pregnancy care. However, if used during pregnancy, monitor for any signs of maternal systemic adverse effects (e.g., weight loss, gastrointestinal symptoms) due to extremely low systemic absorption with topical use. Fetal monitoring not indicated. |
| Fertility Effects | No human data. In animal studies, oral roflumilast had no adverse effects on male or female fertility at exposures up to approximately 100 times the MRHD. With topical use, systemic exposure is minimal; thus, no impact on fertility is expected. |
| ZORYVE (roflumilast) is a phosphodiesterase-4 (PDE4) inhibitor used for plaque psoriasis. Avoid in patients with moderate-to-severe liver impairment (Child-Pugh B/C). Monitor for weight loss; discontinue if unexplained or significant. May cause diarrhea, nausea, or headache; dose reduction not required for mild hepatic impairment. |
| Patient Advice | Apply a thin layer to affected areas once daily; avoid eyes, mouth, and vagina. · Wash hands after application unless treating hands. · Do not use occlusive dressings or bandages unless directed. · Inform your doctor if you experience severe diarrhea, weight loss, or new mood changes. · Avoid use in pregnancy unless clearly needed; not recommended during breastfeeding. · Store at room temperature; keep tube tightly closed. |